The 52-Week-High List: 19 Small Cap Names On Monday
A short list of stocks at their yearly highs raises a key question about price versus underlying business fundamentals.
On Monday, 19 Small Cap US and Canada-listed stocks with a market value above $2 billion are trading at their 52-week highs. The largest name on the list is Apogee Therapeutics (APGE), but the most striking figure belongs to Zeta Global (ZETA), which has gained 43.4% over the last month. That run far outpaces the S&P 500 return of +2.7% over the same period.
The velocity of a move like that raises a critical question for any name on this list: is the business itself delivering the kind of performance that earns such a price? Below are the 10 largest of these 19 names.
The Biggest Names On The List
The table below shows the 10 largest of the 19 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| APGE | $9.41 Bil | 0.1% | 0.2% | 0.7% | 268.9% |
| CRNX | $8.84 Bil | 0.1% | 0.2% | 1.7% | 177.2% |
| ZETA | $7.39 Bil | 1.4% | 8.8% | 43.4% | 58.4% |
| MATX | $6.83 Bil | 0.2% | 1.0% | 11.2% | 115.2% |
| TFX | $6.29 Bil | 1.7% | 2.7% | 4.2% | 13.8% |
| RNG | $5.85 Bil | 0.3% | 3.8% | 25.4% | 127.9% |
| RELY | $5.64 Bil | 0.7% | 0.6% | 17.4% | 44.7% |
| PAGP | $5.59 Bil | 0.9% | 3.5% | 7.2% | 58.1% |
| BOX | $4.98 Bil | 2.3% | 6.9% | 13.4% | 9.0% |
| NSIT | $4.83 Bil | 0.9% | 8.1% | 21.8% | 21.1% |
Is the business keeping pace with the stock price?
Zeta Global (ZETA) shows a business expanding behind its stock’s powerful one-month run. Over the last twelve months, its revenue grew 35.9% and its operating margin is 3.4%. A stock at its high on the back of real growth and positive margins presents a clear narrative.
The picture is different for every company. Matson (MATX), for instance, also sits at a 52-week high, but its revenue declined 0.2% over the last twelve months. It trades at 14.6 times trailing earnings, a multiple applied to a business whose top line has not grown.
A new high is the start of the work, not the end.
A list of stocks at their strongest price of the year is a useful screen for strength. But a price is just a price, not a verdict on a company’s quality or future. The disciplined approach is to treat a 52-week high as a signal to investigate further.
The essential work begins after seeing the high: checking whether the underlying business fundamentals justify the market’s new level of confidence.
Before chasing any name on this list, ask what the company itself expects next. Our Guidance Momentum screen surfaces the stocks whose managements just raised their own outlooks, which is the momentum that tends to have staying power.
Strength Is A Clue. It Is Not A Plan
A stock at its 52-week high has momentum on its side, and momentum is a real force. It is also the most crowded signal in the market, and the difference between a run that lasts and one that tops is always the business underneath.
Checking that business, across thousands of names, is how the Trefis High Quality (HQ) Portfolio is assembled: roughly 30 companies that pass the quality screens, rebalanced on rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the highs point; let the discipline decide.